Schonfeld Strategic Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-75,000	Closed	-$757K	–	2972
2022 Q4	$757K	Buy	75,000 +1,556	+2%	+$15.6K	0.01%	1301
2022 Q3	$729K	Buy	73,444 +58,400	+388%	+$577K	0.01%	1491
2022 Q2	$149K	Sell	15,044 -77,974	-84%	-$765K	﹤0.01%	2021
2022 Q1	$917K	Buy	93,018 +600	+0.6%	+$5.91K	0.01%	1036
2021 Q4	$909K	Buy	92,418 +42,418	+85%	+$416K	0.01%	985
2021 Q3	$487K	Hold	50,000	–	–	0.01%	1284
2021 Q2	$484K	Buy	+50,000	New	+$486K	0.01%	1222

Schonfeld Strategic Advisors's BIOT Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 75,000 shares — an estimated $757K sold.

Schonfeld Strategic Advisors first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $917K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 75,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $757K.
Schonfeld Strategic Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Schonfeld Strategic Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $917K in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.